The PACT-Q is self-administered quest. which was developed as means to investigate patients satisfaction with anticoagulant treatment & treatment convenience in patients with DVT, PE or AF. The PACT-Q2 quest. is made up of two domains: 1) Convenience (13 items): This domain is calculated by adding inverted scores (6-item score) for each of the 13 items in question, &converting to a scale from 0 to 100. 2) Satisfaction with the anticoagulant treatment (7 items):This domain is calculated by adding scores for each of the 7 items in question, & converting to a scale from 0 to 100. The missing items have been replaced by the mean of non-missing items of dimension (if 50% of items were completed, non-missing), in order to calculate domains score. The higher the score, the higher the convenience/satisfaction.

The two domain scores are presented for Visit 2( second assessment), Visit 3 (last assessment) as mean and standard deviation (SD).

Categorical parameters of the patient characteristics at baseline included age, Risk factors associated with stroke and/or haemorrhage in the medical history (MH), co-morbidities (CoMo), concomitant medication (CM) and dosing of Pradaxa® (DoP).

Haemorrhagic risk (HAS-BLED) is categorized as Low risk (score 0), Moderate risk (score 1-2) and High Risk (score ≥3). Thromboembolic risk (CHA2DS2-VASc) is categorized as Low risk (score 0 in male and 1 in female), Moderate risk (score 1 in male and 2 in female) and High Risk (score ≥2 in male and ≥3 in female).

Stages of kidney disease are categorized based on Cockcroft-Gault review as below:

No kidney failure (> 80 ml/min), Mild kidney failure (50-80 ml/min), Moderate kidney failure (30-49 ml/min), Severe kidney failure (15-29 ml/min) and End-stage kidney failure/dialysis (< 15 ml/min).

Creatinine clearance at baseline is a measure of the patient's kidney function and is one of the baseline patient characteristics.

Vitamin K Antagonist (VKA) treatment duration is one of the baseline patient characteristics.

Categories of reasons for switching from VKAs to Pradaxa® are as below:

1. Hypersensitivity (Hypersensitivity to the drug)
2. Intracranial haemorrhage (Patients with a history of intracranial haemorrhage (ICH) (except during the acute phase) in whom the benefits of anticoagulation were deemed to outweigh the risk of haemorrhage)
3. Ischaemic stroke (Patients with ischaemic stroke who present clinical and neuroimaging criteria indicating a high risk of ICH)
4. Arterial thromboembolic episodes (Patients undergoing treatment with VKAs, suffering from severe arterial thromboembolic episodes despite good INR control)
5. INR not in range (Patients who have started treatment with VKAs in whom it is not possible to keep the INR in range (2-3) despite good therapeutic compliance)
6. INR management (Lack of access to conventional INR management)
7. Pts decision (Patient's decision)
8. Others.

A single patient may have specified more than one reason

Reasons for for changing the dose of Pradaxa®: 150 mg/bid to 110 mg/bid are categorized as below:

1] High risk of bleeding 2] Moderate renal failure 3] >80 years 4] Other reason

Reasons for for changing the dose of Pradaxa®: 110 mg/bid to 150 mg/bid are categorized as below:

1] High risk of bleeding 2] Moderate renal failure 3] >80 years 4] Other reason

Reasons for no longer receiving Pradaxa® treatment categorized as below:

1. Treatment change (Change of treatment (by patient or by investigator)
2. Adverse event (Diarrhea, gastrointestinal discomfort, rectorrhagia, dyspepsia)
3. Exitus
4. Others

Race information is provided. Ethnicity information was not collected for this study.

The PACT-Q is self-administered quest. which was developed as means to investigate patients satisfaction with anticoagulant treatment & treatment convenience in patients with deep venous thrombosis (DVT), pulmonary embolism (PE) or atrial fibrillation (AF). The PACT-Q2 quest. is made up of two domains: 1) Convenience (13 items): This domain is calculated by adding inverted scores (6-item score) for each of the 13 items in question, &converting to a scale from 0 to 100. 2) Satisfaction with the anticoagulant treatment (7 items):This domain is calculated by adding scores for each of the 7 items in question, & converting to a scale from 0 to 100.

The missing items have been replaced by the mean of non-missing items of the dimension (if 50% of items were completed, non-missing), in order to calculate domains score. The higher the score, the higher the convenience/satisfaction.

The two domain scores are presented for Baseline, Visit 3 (last assessment) as mean and standard deviation (SD).

Eligible pts: All pts fulfilling all inclusion criteria and no exclusion criteria.The analyses were performed based on actual anticoagulant treatment (AT) received by pts (i.e. "as-treated" analysis),so that pts who discontinued the initial AT during time of an assessment were excluded from all analyses where data from that assessment was included

The PACT-Q is self-administered quest. which was developed as means to investigate patients satisfaction with anticoagulant treatment & treatment convenience in patients with DVT, PE or AF. The PACT-Q2 quest. is made up of two domains: 1) Convenience (13 items): This domain is calculated by adding inverted scores (6-item score) for each of the 13 items in question, &converting to a scale from 0 to 100. 2) Satisfaction with the anticoagulant treatment (7 items):This domain is calculated by adding scores for each of the 7 items in question, & converting to a scale from 0 to 100. The missing items have been replaced by the mean of non-missing items of dimension (if 50% of items were completed, non-missing), in order to calculate domains score. The higher the score, the higher the convenience/satisfaction.

The two domain scores are presented for Visit 2( second assessment), Visit 3 (last assessment) as mean and standard deviation (SD).

Eligible pts: All pts fulfilling all inclusion criteria and no exclusion criteria. The analyses were performed based on actual anticoagulant treatment (AT) received by pts (i.e. "as-treated" analysis),so that pts who discontinued the initial AT during time of an assessment were excluded from all analyses where data from that assessment was included

CHA2DS2-VASc stroke risk score is calculated based on following conditions: Congestive heart failure/left ventricular dysfunction, Hypertension, Age (≥ 75), Diabetes Mellitus,Stroke/Transient Ischaemic Attack (TIA)/thromboembolism,Vascular disease (history of myocardial infarction, peripheral artery disease or aortic plaque) ,Age 65-74, Sex category. HAS-BLED bleeding risk score is calculated based on following conditions: Uncontrolled hypertension with Systolic Blood pressure (SBP) ≥ 160 mmHg,Kidney failure,liver failure,History of stroke,History of bleeding, anaemia or predisposition to bleeding,Unstable/high or poor international normalized ratio (INR) (<60% of time within therapeutic range),Elderly (>65 years),Medications that affect haemostasis,Consumptions of ≥8 alcoholic drinks per week.CHA2DS2-VASc stroke risk score & HAS-BLED bleeding risk score range from 0 to 9 with 0 being outcome with low stroke risk for CHA2DS2-VASc and being with low bleeding risk for HAS-BLED.

Eligible pts: All pts fulfilling all inclusion criteria and no exclusion criteria.

Categorical parameters of the patient characteristics at baseline included age, Risk factors associated with stroke and/or haemorrhage in the medical history (MH), co-morbidities (CoMo), concomitant medication (CM) and dosing of Pradaxa® (DoP).

Haemorrhagic risk (HAS-BLED) is categorized as Low risk (score 0), Moderate risk (score 1-2) and High Risk (score ≥3). Thromboembolic risk (CHA2DS2-VASc) is categorized as Low risk (score 0 in male and 1 in female), Moderate risk (score 1 in male and 2 in female) and High Risk (score ≥2 in male and ≥3 in female).

Stages of kidney disease are categorized based on Cockcroft-Gault review as below:

No kidney failure (> 80 ml/min), Mild kidney failure (50-80 ml/min), Moderate kidney failure (30-49 ml/min), Severe kidney failure (15-29 ml/min) and End-stage kidney failure/dialysis (< 15 ml/min).

Eligible pts: All pts fulfilling all inclusion criteria and no exclusion criteria.

Creatinine clearance at baseline is a measure of the patient's kidney function and is one of the baseline patient characteristics.

Eligible pts: All pts fulfilling all inclusion criteria and no exclusion criteria.

Vitamin K Antagonist (VKA) treatment duration is one of the baseline patient characteristics.

Eligible pts: All pts fulfilling all inclusion criteria and no exclusion criteria.

Categories of reasons for switching from VKAs to Pradaxa® are as below:

1. Hypersensitivity (Hypersensitivity to the drug)
2. Intracranial haemorrhage (Patients with a history of intracranial haemorrhage (ICH) (except during the acute phase) in whom the benefits of anticoagulation were deemed to outweigh the risk of haemorrhage)
3. Ischaemic stroke (Patients with ischaemic stroke who present clinical and neuroimaging criteria indicating a high risk of ICH)
4. Arterial thromboembolic episodes (Patients undergoing treatment with VKAs, suffering from severe arterial thromboembolic episodes despite good INR control)
5. INR not in range (Patients who have started treatment with VKAs in whom it is not possible to keep the INR in range (2-3) despite good therapeutic compliance)
6. INR management (Lack of access to conventional INR management)
7. Pts decision (Patient's decision)
8. Others.

A single patient may have specified more than one reason

Eligible pts: All pts fulfilling all inclusion criteria and no exclusion criteria.

Reasons for for changing the dose of Pradaxa®: 150 mg/bid to 110 mg/bid are categorized as below:

1] High risk of bleeding 2] Moderate renal failure 3] >80 years 4] Other reason

Eligible pts: All pts fulfilling all inclusion criteria and no exclusion criteria.

Reasons for for changing the dose of Pradaxa®: 110 mg/bid to 150 mg/bid are categorized as below:

1] High risk of bleeding 2] Moderate renal failure 3] >80 years 4] Other reason

Eligible pts: All pts fulfilling all inclusion criteria and no exclusion criteria.

Reasons for no longer receiving Pradaxa® treatment categorized as below:

1. Treatment change (Change of treatment (by patient or by investigator)
2. Adverse event (Diarrhea, gastrointestinal discomfort, rectorrhagia, dyspepsia)
3. Exitus
4. Others

Eligible pts: All pts fulfilling all inclusion criteria and no exclusion criteria.